Katherine Holcomb, MD
Dermatology · Metairie, LANPI 1861668808
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $287,451 of the $411,401 with a category attached, or 69.9%. AbbVie accounts for 62.7% of it on its own, with 43 other manufacturers making up the rest. Reporting peaked in 2023 at $115,659 and has fallen 53.7% since, to $53,601 in 2025. Among dermatology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,403 payments — averaging $293.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$258K
- Galderma Laboratories, L.p.$118K
- Almirall LLC$10K
- Incyte Corporation$8K
- E.r. Squibb & Sons, L.L.C.$4K
- Johnson & Johnson$1K
- plus $11K from 38 others
Across 36 payments — averaging $7898.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$280K
- Galderma Research & Development, LLC$4K
What the payments were for
- Consulting fees$72,80618%
- Speaking & faculty fees$287,45170%
- Travel & lodging$23,8446%
- Food & beverage$26,7186%
- Education$5820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$411,401 in reported general payments places this provider in the 95th percentile of 189 dermatology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Clobetasol Propionate | 28 | $1,461 |
| ValacyclovirValacyclovir Hcl | 25 | $1,400 |
| Tretinoin | 15 | $1,155 |
| Fluorouracil | 18 | $923 |
| Dutasteride | 24 | $741 |
| Clindamycin Phosphate | 12 | $349 |
| Minoxidil | 19 | $196 |
| Triamcinolone Acetonide | 19 | $81 |
| Mupirocin | 11 | $79 |
| Finasteride | 14 | $77 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Metairie
- Robert KoppelMetairie$212K
- Elizabeth GrieshaberMetairie$156K
- Rachael Delahoussaye-ShieldsMetairie$83K
- Michelle GerdesMetairie$20K
- Diane RoseMetairie$9K
- Barbara BoppMetairie$9K
- William ClaiborneNew Orleans$374K
- Blair BuddenLafayette$329K
- Erin BohNew Orleans$277K
- Mara HaseltineNew Orleans$276K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.